Mesenchymal stem cells in the treatment of severe COVID-19

by stemedica admin | Sep 20, 2021 | Publications

Santosh Kesari1,2*, Gregory C. Kasper3*, Lev Verkh4 , Terese C. Hammond5 , Marla L. Matal3 , Jay W. Hammerling3 , Nikolai Tankovich4 , Adrianus P. Lim3 , Kevin H. Zhao3 , Tifany Juarez1 , Roberta E. Redfern3 , Jaya M. Gill6 , Natsuko Nomura1 , Audrey Hiemer1 , Annie...

StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device

by stemedica admin | Aug 22, 2021 | Company Initiatives

Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...

Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells

by stemedica admin | Aug 5, 2021 | Clinical Trials

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its...

Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19

by stemedica admin | May 23, 2021 | Company Initiatives

SAN DIEGO, California, May 24, 2021 – Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the...

FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients

by stemedica admin | Sep 27, 2020 | Clinical Trials

SAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for “A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess...